

From: Ford, Wes
Sent: Monday, 17 January 2022 2:34 PM
To: Russmann, Claudia
Cc: Richards, Sarah
Subject: RE: Sheppards antibiotics monitoring - to be finalised

Claudia

I agree we should be releasing information about use of medications that we are requiring to be monitored.

Thanks

Wes

Wes Ford | Director and Chief Executive Officer
Environment Protection Authority
GPO BOX 1550, HOBART, TAS, 7001
T: (03) 61654523 | M: [REDACTED]
E: Wes.Ford@epa.tas.gov.au
W: www.epa.tas.gov.au



From: Russmann, Claudia <Claudia.Russmann@epa.tas.gov.au>
Sent: Friday, 14 January 2022 12:33 PM
To: Ford, Wes <Wes.Ford@epa.tas.gov.au>
Cc: Richards, Sarah <Sarah.Richards@epa.tas.gov.au>
Subject: Sheppards antibiotics monitoring - to be finalised

Hi Wes,

The draft antibiotics monitoring schedule for Sheppards has been reviewed by Tassal and I've had discussions with [REDACTED]. They have requested that we drop the number of pen bays to be monitored from 5 to 4, which I think we can accommodate. This is a reduction from the generic monitoring schedule, but is justifiable given that the compact nature of the lease and relatively small variance in sediment concentrations under pen bays which we've observed at Okehampton.

Tassal have engaged Aquenal to start sampling next Thursday which is the last day of medication. I can get the monitoring schedule package finalised and forwarded to you for signature by Tuesday.

One sticking point however is our previous request for the final monitoring report to be made available to the public. The issue came up in relation to the Okehampton Bay 2020 monitoring program but was never resolved. The

key information can be accessed here [EN-EM-PE-FI-251567-001.009 - Antibiotics dosing 2020 - reporting](#); short summary below:

- Sept 2020: EPA received final monitoring report and endorsed it by letter, highlighting intention to make it available on the EPA website. The report contained information regarding the medication event (total amount & pen bays dosed);
- Oct 2020: Tassal sent letter [REDACTED] providing number of legal reasons why release of the report in that form was not acceptable to them (incl commercial in confidence argument).
- Oct 2020: EPA responded to Tassal letter, stating intent to publish on 16 Nov 2020 unless Tassal could provide further justification why not.
- 16 Nov 2020: Tassal submitted revised report omitting the treatment information
- 22 Feb 2021: Your email to [REDACTED] expressing the view the report should be published with the treatment information included.
- I could not find any further documentation after that date.
- When I talked to [REDACTED] earlier, he was actually under the impression that a version of the report had been published but that is not the case.

Can you please consider this issue and give me guidance which way to go, as it should be mentioned in the cover letter?

My personal view is that we should release the information on our website.

Cheers, Claudia

Claudia Russmann | Senior Environmental Officer
Salmon Environmental Management Section | ph, 6165 4567
Environment Protection Authority



From: [REDACTED] <[REDACTED]@tassal.com.au>
Sent: Tuesday, 11 January 2022 7:30 PM
To: Russmann, Claudia <Claudia.Russmann@epa.tas.gov.au>
Cc: Gallagher, Stephen G <Stephen.Gallagher@epa.tas.gov.au>; Ford, Wes <Wes.Ford@epa.tas.gov.au>; Salmon Regulation <Salmon.Reg@epa.tas.gov.au>; [REDACTED] <[REDACTED]@tassal.com.au>
Subject: RE: Antibiotics monitoring requirements

